Restrictive Lung Disease

Is Prone Ventilation Limited for Patients With Mild or Moderate ARDS?

By

Bryant Moeller

Publish Date October 14, 2019

Researchers question previous recommendations that demonstrated that prone ventilation reduced mortality in patients with acute respiratory distress syndrome.

Pirfenidone May Benefit Unclassifiable Progressive Fibrosing Interstitial Lung Disease

By

Pulmonology Advisor Contributing Writer

Publish Date October 10, 2019

Although the planned statistical model could not be applied to primary end point data, key secondary end point analysis suggested that patients with progressive fibrosing unclassifiable interstitial lung disease could benefit from pirfenidone.

Nintedanib Associated With Lower Rate of FVC Decline in Interstitial Lung Disease

Publish Date October 4, 2019

Nintedanib was linked to a lower rate of decline in forced vital capacity vs placebo in a phase 3 trial.

Obesity Linked to Underutilization of Low Tidal Volume Ventilation in ARDS

By

Rachael Beairsto

Publish Date October 21, 2019

ARDS was underrecognized in the study population across all body mass indexesBMIs, but this underrecognition did not explain why patients with class 3 obesity were more likely to meet ARDS criteria but not receive low tidal volume ventilation.

Combination Metformin and Low-Dose Nintedanib Reduces Pulmonary Fibrosis

By

Pulmonology Advisor Contributing Writer

Publish Date October 21, 2019

Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.

Statins Taken Before Septic Shock May Reduce ARDS Risk

By

Britt Gambino

Publish Date October 20, 2019

Statin therapy before septic shock may decrease the risk for acute respiratory distress syndrome.

ILD Associated With More Muscle Mass, Less Bone Density Loss

By

Meghna Rao

Publish Date October 19, 2019

Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.

Plasma Biomarkers of Idiopathic Pulmonary Fibrosis May Predict Survival

By

Pulmonology Advisor Contributing Writer

Publish Date September 26, 2019

Plasma biomarkers of progressive idiopathic pulmonary fibrosis may be markers of progressive pulmonary fibrosis regardless of the type of interstitial lung disease.

Prehospital Vulnerability Associated With 1-Year Mortality in ARDS

By

Pulmonology Advisor Contributing Writer

Publish Date September 12, 2019

Prehospital vulnerability was associated with higher 1-year mortality but not with acute respiratory distress syndrome or short-term mortality.

FDA Approves Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease

By

Brian Park, PharmD

Publish Date September 12, 2019

The FDA has approved Ofev capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD.

RV to LV Diameter Ratio May Predict Mortality in Interstitial Lung Disease

By

Sheila Jacobs

Publish Date August 13, 2019

An increased right to left ventricle diameter ratio may help identify high-risk patients with suspected interstitial lung disease/pulmonary hypertension.